ReviewFrontiers in medicine2026

Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.

Tao He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.